AMENDMENTS TO THE CLAIMS:

Listing of Claims

1. Pharmaceutical product with active ingredients affecting the central nervous system, with addition of a substance active in the nasal mucous membrane for endonasal administration, ~~characterized in that~~ wherein a combined composition of free radical products with biologically active substances are administered for potentiating the efficacy, wherein the increased efficacy occurs in combination with oxygen anion radicals (SAR) and/or nitrogen oxide active products.

2. Pharmaceutical product according to claim 1, ~~characterized in that~~ wherein the potentiation is attained by drug-like substances and different types of metabolites, and such substances of a chemical nature.

3. Pharmaceutical product according to claim 1, ~~characterized in that~~ wherein the potentiation is attained in conjunction with different types of free radicals (SAR, NO-radicals) and/or corresponding radical formers.

4. Pharmaceutical product according to claim 1, ~~characterized in that~~ wherein the substances active in the nasal mucous membrane are perhydroxyl radicals, hydrogen peroxide, hydroperoxide radicals or their hydrate clusters.

5. Pharmaceutical product according to claim 1, ~~characterized in that~~ wherein the substances active in the nasal mucous membrane are forms of nitrogen monoxide (NO) and their precursors or reaction products.

6. Pharmaceutical product according to claim 1, ~~characterized in that~~ wherein the substances active in the nasal mucous membrane are biochemical, physiological vaso-dilators, preferably arginin, bradykinin, urea or eicosatric acid-derivates.

7. Pharmaceutical product according to claims 1 ~~to 6, characterized by~~ wherein utilizing a mixture comprising substances active in the nasal mucous membrane in a concentration of 10^{-12} mole/l to 10^{-1} mole/l.

8. Pharmaceutical product according to claims 1 ~~to 6, characterized by~~ , wherein utilizing a mixture comprising substances active in the nasal mucous membrane in a concentration of 10^{-5}.

9. Pharmaceutical product according to claims 1 ~~to 8, characterized in that~~ wherein conventional drug substances are included in a dose of 0.001 mg to 100 mg per dosage unit.

10. Pharmaceutical product according to claims 1 ~~to 9, characterized in that~~ , wherein the metabolite is included in a dose of 0.0001 mg to 100 mg per dosage unit.

11. Pharmaceutical product according to claims 1 ~~to 10, characterized in that~~ , wherein the drug substances are promedol, metamizol, phenobarbital, methadone, tramadol, ASS or sildenafil.

12. Pharmaceutical product according to claim ~~12~~ 1, ~~characterized in that~~ wherein the metabolite is tryptophan, gamma-amino butyric acid, oxytocin, dermorphin, cyclic GMP, glucose, dopamine, or L-dopa.

13. Pharmaceutical product according to claims 1 ~~to 13, characterized in that~~ , wherein one or more of its active components are present in the composition as liposomes and/or nanosomes.

14. Pharmaceutical product according to claims 1 ~~to 14, characterized in that~~ wherein one or more of its active components are present in the composition in a form different from the solution.

15. Pharmaceutical product according to claims 1 ~~to 15, characterized in that~~ , wherein pharmaceutically acceptable, auxiliary substances are present in the composition.

16. Pharmaceutical product according to claims 1 ~~to 16, characterized in that~~ , wherein the auxiliary substances are stabilizers, antioxidants, pH regulators, osmo-regulators or antimicrobial substances, which are present in the product in combination with a pharmaceutical substance adequate for its administration.

17. Pharmaceutical product according to claims 1 ~~to 17, characterized in that~~ , wherein the product is a spray that can be endonasally administered.